Immunotherapy regimes dependent on ApoE status
First Claim
Patent Images
1. A method of treating a disease characterized by Aβ
- deposits in the brain of patient comprising intravenously or subcutaneously administering an effective regime of a humanized antibody to a population of patients suffering from the disease;
wherein the humanized antibody comprises a mature light chain variable region sequence of SEQ ID NO;
2 and a mature heavy chain variable region sequence of SEQ ID NO;
3, and a human heavy chain constant region of IgG1 isotype with L234A, L235A, and G237A mutations, wherein positions are numbered by the EU numbering system, and thereby treating the disease in the patients, wherein the regime administered to different patients in the population does not depend on the number of ApoE4 alleles present in a patient.
11 Assignments
0 Petitions
Accused Products
Abstract
The invention provides methods of immunotherapy of Alzheimer'"'"'s and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.
-
Citations
27 Claims
-
1. A method of treating a disease characterized by Aβ
- deposits in the brain of patient comprising intravenously or subcutaneously administering an effective regime of a humanized antibody to a population of patients suffering from the disease;
wherein the humanized antibody comprises a mature light chain variable region sequence of SEQ ID NO;
2 and a mature heavy chain variable region sequence of SEQ ID NO;
3, and a human heavy chain constant region of IgG1 isotype with L234A, L235A, and G237A mutations, wherein positions are numbered by the EU numbering system, and thereby treating the disease in the patients, wherein the regime administered to different patients in the population does not depend on the number of ApoE4 alleles present in a patient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- deposits in the brain of patient comprising intravenously or subcutaneously administering an effective regime of a humanized antibody to a population of patients suffering from the disease;
-
15. A method of reducing the risk, lessening the severity or delaying the outset of a disease characterized by Aβ
- deposits in the brain of patient comprising administering an effective regime of a humanized antibody to a population of patients susceptible to the disease;
wherein the humanized antibody comprises a mature light chain variable region sequence of SEQ ID NO;
2 and a mature heavy chain variable region sequence of SEQ ID NO;
3, and a human heavy chain constant of IgG1 isotype with L234A, L235A, and G237A mutations, wherein positions are numbered by the EU numbering system, thereby reducing the risk, lessening the severity or delaying the outset of the disease in the patients, wherein the regime administered to different patients in the population does not depend on the number of ApoE4 alleles present in a patient. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
- deposits in the brain of patient comprising administering an effective regime of a humanized antibody to a population of patients susceptible to the disease;
Specification